secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001129928-26-000009
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics launches Phase 2 REO 033 trial in 2L RAS-mutant MSS mCRC; preliminary data expected by end of 2026
--------------------------------------------------------------------------------

- Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.
- Primary endpoint is ORR; secondary endpoints include PFS, OS, safety, and biomarker analysis; first site expected this month.
- Prior REO 022 study showed median OS 27 months and PFS 16.6 months, vs 11.2 and 5.7 months for standard of care.
- Pelareorep combination recently granted FDA Fast Track Designation for this indication.
- Lead investigator is Dr. Sanjay Goel (Rutgers Cancer Institute); preliminary data by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000009/0001129928-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000009/oncy-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer